HC Biopharma Inc.

Privately held: no public share price

Assets

(2 total)
2Total Assets
0Approved
0Phase 3 / Filed
2Phase 1–2 / Early
2Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Phase 2
PD-1 / CTLA-4 / VEGFMultispecific antibody
Non-Small Cell Lung Cancer
Phase 1
Undisclosed / early pipeline
Systemic Lupus Erythematosus

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
HC010Phase 2NSCLC
Est. primary completion 2026-12-30 · NCT07169552 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

No financial reports recorded.